Skip to main content

IDWeek 2024 Main banner

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Presentation Icons

Live Streamed

On Demand

Back

Christopher M. Longshaw, PhD

Senior Director, Scientific Affairs EU
Shionogi B.V., United Kingdom

Disclosure(s): Shionogi BV: Employee

Poster(s):

(P-650) In vitro Activity of Cefiderocol and Comparator Agents Against Global Enterobacterales Isolates From Hospitalized Patients with Pneumonia Collected as Part of the SENTRY Surveillance Program (2020-2022)

Thursday, October 17, 2024
12:15 PM – 1:30 PM US PT
(P-1099) Correlation Analysis of Cefiderocol In vitro Activity and In vivo Efficacy Against Acinetobacter baumannii Strains with Difficult-to-Read MIC Endpoints

Friday, October 18, 2024
12:15 PM – 1:30 PM US PT
(P-1100) Activity of Cefiderocol and Comparator Agents Against Global Isolates of Stenotrophomonas maltophilia from the SENTRY Antimicrobial Surveillance Program (2020–2023)

Friday, October 18, 2024
12:15 PM – 1:30 PM US PT
(P-1472) Cefiderocol Remains Highly Active Against Carbapenemase-Producing Enterobacterales

Friday, October 18, 2024
12:15 PM – 1:30 PM US PT
(P-1475) Real-World Effectiveness and Safety of Cefiderocol in the Treatment of Patients with Serious Gram-negative Bacterial Infections: Results of the PROVE Chart Review Study

Friday, October 18, 2024
12:15 PM – 1:30 PM US PT
(P-1484) In vitro Activity of Cefiderocol and Comparator Agents Against Non-fermentative Gram-negative Bacilli Isolated from Patients Hospitalized with Pneumonia as part of the SENTRY Global Surveillance Program (2020-2022)

Friday, October 18, 2024
12:15 PM – 1:30 PM US PT